Patient-friendly summary
If you read nothing else
Bottom line
Botulinum toxin A has a reasonable biological rationale for myofascial pain, but the trial evidence for neck and back MPS is contradictory and cannot recommend or reject it; it may be worth considering off-label for refractory cases or specific sites like piriformis syndrome.
Preliminary evidencePublished
Evidence hierarchy
Study participants
Patients with myofascial pain syndrome of the neck or back treated with botulinum toxin (across the reviewed trials; two largest trials had 142 and 144 patients)
Study Summary
This clinical-perspective narrative review examines why clinical trials of botulinum toxin A (BTA) for myofascial pain syndrome (MPS) of the neck and back have produced contradictory results. The authors performed a content analysis of 19 clinical trials and 15 systematic reviews, identifying major sources of variability across diagnostic criteria, muscles injected, injection technique, number of trigger points injected, BTA dose, control-group treatments, outcome measures, and follow-up duration. They conclude that, although BTA has a plausible pharmacological and pathophysiological rationale, the inconsistent evidence does not allow the treatment to be either recommended or rejected for MPS in general. The authors suggest BTA may be useful in specific situations such as piriformis syndrome and in refractory MPS that has not responded to other myofascial injection therapies.
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| Trial results on BTA for MPS are contradictory | Of the trials reviewed, most reported BTA was not superior to comparison treatments, but four high-quality clinical trials found BTA superior to control. Notably, in all studies, patients in both BTA and control arms showed significant pain improvement versus their own pre-treatment levels. | High |
| Diagnostic and selection criteria varied widely between trials | There is no definitive consensus on MPS diagnostic criteria. The two largest trials (Ferrante, n=142; Göbel, n=144) used such different criteria that Ferrante excluded patients with more than 5 active trigger points while Göbel required at least 10 — meaning neither trial's patients would have qualified for the other. | High |
| Injection technique, dose, and number of trigger points were highly inconsistent | Number of injection sites ranged from 1 to 10. Total onabotulinumtoxinA dose varied sevenfold (35 U to 250 U); abobotulinumtoxinA varied 16-fold (25 U to 400 U). Dilutions varied up to 10-fold. The only dose-comparison trial (10, 25, 50 U per trigger point) found no dose-dependent effect. | High |
| So-called placebo controls were actually active treatments | Normal saline injection, local anaesthetic injection, and dry needling — used as 'placebo' controls — are all procedures of known efficacy. This means many studies were superiority comparisons between two active treatments rather than placebo-controlled trials, with implications for sample-size calculation. | High |
| BTA may be useful in specific conditions rather than MPS in general | Reviewers' conclusions clustered into three types: not recommended, insufficient data to recommend or reject, and recommended only for specific conditions. Some reviews supported use for piriformis syndrome, chronic lumbar pain, and refractory MPS that has not responded to other treatments. | Medium |
| BTA has a plausible mechanistic rationale for MPS | BTA blocks acetylcholine release at the neuromuscular junction and, in experimental studies, directly inhibits pain mediators (substance P, bradykinin, CGRP, glutamate) and may act on the sensitization phenomenon — addressing the excess ACh, local nociception, and sensitization thought to underlie trigger points. | Medium |
| Follow-up duration was often suboptimal | Follow-up varied between 4 weeks and 6 months. Given evidence that BTA's effect may persist around 12 weeks, short or crossover follow-up windows may have masked treatment effects; the authors suggest follow-up should probably continue for 3 to 6 months. | Medium |
Of the trials reviewed, most reported BTA was not superior to comparison treatments, but four high-quality clinical trials found BTA superior to control. Notably, in all studies, patients in both BTA and control arms showed significant pain improvement versus their own pre-treatment levels.
There is no definitive consensus on MPS diagnostic criteria. The two largest trials (Ferrante, n=142; Göbel, n=144) used such different criteria that Ferrante excluded patients with more than 5 active trigger points while Göbel required at least 10 — meaning neither trial's patients would have qualified for the other.
Number of injection sites ranged from 1 to 10. Total onabotulinumtoxinA dose varied sevenfold (35 U to 250 U); abobotulinumtoxinA varied 16-fold (25 U to 400 U). Dilutions varied up to 10-fold. The only dose-comparison trial (10, 25, 50 U per trigger point) found no dose-dependent effect.
Normal saline injection, local anaesthetic injection, and dry needling — used as 'placebo' controls — are all procedures of known efficacy. This means many studies were superiority comparisons between two active treatments rather than placebo-controlled trials, with implications for sample-size calculation.
Reviewers' conclusions clustered into three types: not recommended, insufficient data to recommend or reject, and recommended only for specific conditions. Some reviews supported use for piriformis syndrome, chronic lumbar pain, and refractory MPS that has not responded to other treatments.
BTA blocks acetylcholine release at the neuromuscular junction and, in experimental studies, directly inhibits pain mediators (substance P, bradykinin, CGRP, glutamate) and may act on the sensitization phenomenon — addressing the excess ACh, local nociception, and sensitization thought to underlie trigger points.
Follow-up varied between 4 weeks and 6 months. Given evidence that BTA's effect may persist around 12 weeks, short or crossover follow-up windows may have masked treatment effects; the authors suggest follow-up should probably continue for 3 to 6 months.
Strengths
- Synthesizes a large body of evidence (19 trials and 15 systematic reviews) from a practical clinical perspective
- Clearly itemizes specific, concrete sources of between-study variability (diagnosis, muscles, technique, dose, controls, outcomes, follow-up)
- Highlights the underappreciated point that common 'placebo' controls (saline, local anaesthetic, dry needling) are themselves active treatments
- Grounds clinical recommendations in the article's own hedged reading of the evidence, including identifying subgroups (piriformis, refractory pain) that may benefit
Limitations
- Explicitly a qualitative narrative review and not a systematic review, so it does not pool data or formally grade evidence quality
- No quantitative meta-analysis or pooled effect estimates are provided
- The underlying trials themselves are heterogeneous and contradictory, limiting the strength of any conclusion
- Use of BTA for MPS remains off-label, and the review cannot establish definitive efficacy
- Selection of trials and reviews was based on PubMed searches without a formal pre-registered systematic protocol
Key Takeaways for Patients
What This Means for You
- 01Botulinum toxin (Botox-type) injections for muscle/myofascial pain in the neck and back have shown conflicting results across studies, so experts cannot clearly recommend or rule out this treatment in general.
- 02In nearly all studies, people improved after injection regardless of whether they received botulinum toxin or a comparison injection such as saline or local anaesthetic — the needle itself and other factors may contribute to relief.
- 03Botulinum toxin may be more helpful in specific situations, such as piriformis syndrome or when pain has not responded to other injection treatments.
- 04This is an off-label use; if it is considered, a doctor should explain the uncertainty and obtain informed consent.
- 05Differences in how studies were done — diagnosis, which muscles were injected, dose, technique, and follow-up time — help explain why results disagree, so individual responses can vary.
Read the Full Paper
Access the complete peer-reviewed study from Evidence-based Complementary and Alternative Medicine : eCAM
View Full Study